New monoclonal antibodies or fusion proteins that specifically target B-cell survival or proliferation are, however, now becoming available. BCMA Stimulates plasma cell survival and IgM production ...

“At one point in time, you probably don’t have B cells in the body,” he said. “The only cell surviving that attack is actually the plasma cell, because the plasma cell has no CD19 on its ...

People commonly refer to these as B cells and T cells. The job of T cells is to help the body kill cancer cells and control the immune response to foreign substances. They do this by destroying ...

The measles virus attacks long-lived immune cells, reducing antibody-mediated protection from other infectious diseases and ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

Plasma cell leukemia (PCL) is a rare disease that may present de novoor secondary to plasma cell myeloma. Advanced disease and extramedullary involvement are common clinical features at presentation.

a transcription factor necessary for the transient expansion of B cells preceding plasma cell differentiation, via coupling its translation to its decay. Immune checkpoint blockade therapy for ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.